Weight management can be challenging, especially when excess weight is associated with insulin resistance, type 2 diabetes, hormonal changes or other metabolic health concerns. For eligible adults, prescription weight loss injections may be considered as part of a medically supervised weight management plan.
Dr. Komal Kulkarni, Consultant Physician and Diabetologist in Bavdhan, Pune, provides medical evaluation and guidance for patients considering weight loss injections such as tirzepatide (Mounjaro) and semaglutide (Wegovy). Treatment decisions are based on medical history, body mass index (BMI), existing health conditions and individual treatment goals.
Weight loss injections are prescription medicines that act on hormone pathways involved in appetite regulation, fullness and blood glucose control. Certain medicines are approved for chronic weight management in eligible patients when combined with dietary changes and regular physical activity.
These medicines may help reduce hunger, improve feelings of fullness and support gradual weight reduction. However, they are not suitable for everyone, and treatment requires medical assessment and ongoing monitoring.
Weight loss injections work by influencing hormonal signals that regulate appetite, digestion and blood sugar levels.
Appetite regulation: Certain medicines act on pathways in the brain involved in hunger and food intake.
Increased fullness: Patients may feel satisfied after eating smaller portions.
Slower gastric emptying: Some medicines delay stomach emptying, particularly during the initial treatment period.
Blood glucose regulation: GLP-1-based medicines influence insulin and glucagon responses in a glucose-dependent manner.
Weight management support: Reduced calorie intake, combined with lifestyle measures, may contribute to weight loss over time.
The response varies between individuals. The medicine, dose and duration of treatment should be determined by a qualified medical practitioner.
Mounjaro contains tirzepatide, a medicine that acts on both GIP and GLP-1 receptors. These pathways are involved in appetite regulation, blood glucose control and energy balance.
Tirzepatide may be prescribed for eligible adults with obesity or overweight associated with certain weight-related health conditions, according to its approved indications.
It is generally administered once weekly by subcutaneous injection. The starting dose and subsequent adjustments depend on clinical assessment, tolerability and prescribing guidance.
Wegovy contains semaglutide, a GLP-1 receptor agonist used for chronic weight management in eligible patients.
Semaglutide acts on appetite-related pathways and can help patients feel fuller, reduce hunger and lower food intake. It is used alongside dietary modifications and increased physical activity.
Wegovy is generally administered once weekly, with gradual dose escalation to help manage gastrointestinal side effects.
Important: Mounjaro and Wegovy are not interchangeable without medical guidance. Their indications, dosing schedules, contraindications and precautions differ. They should not be combined with each other or with another GLP-1-based medicine unless specifically supported by approved prescribing guidance.
Prescription weight loss injections may be considered for adults who meet the eligibility criteria for the specific medicine.
A medical assessment may include:
BMI of 30 kg/m² or above, or a lower BMI threshold where permitted by the medicine's approved prescribing information.
BMI of 27 kg/m² or above with a weight-related health condition, where applicable.
Type 2 diabetes, high blood pressure, abnormal cholesterol levels or obstructive sleep apnoea.
Previous difficulty achieving sufficient weight reduction through structured lifestyle interventions.
A need for long-term, medically supervised weight management.
BMI alone does not determine whether treatment is appropriate. The doctor also considers waist circumference, metabolic health, medical history, existing medications and individual risk factors.
Weight loss injections may be unsuitable for certain patients, including those who are pregnant, planning pregnancy or breastfeeding. Additional precautions may apply to people with a history of pancreatitis, significant gastrointestinal disease, gallbladder problems, or certain thyroid conditions.
Contraindications differ between medicines. Patients should disclose their complete medical and family history before treatment begins.
When prescribed appropriately, weight loss injections may support:
Reduction in body weight over time.
Better appetite and portion control.
Improvements in certain metabolic health measurements.
Better blood glucose management in some patients.
Reduction in waist circumference.
Support for sustained weight management when combined with lifestyle changes.
The amount of weight lost depends on the medicine, treatment duration, dose, lifestyle habits and individual response. Not everyone achieves the same results, and weight regain can occur after stopping treatment.
Like all prescription medicines, weight loss injections can cause side effects.
Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite. These symptoms may be more noticeable when starting treatment or increasing the dose.
Less common but potentially serious complications include pancreatitis, gallbladder disease, dehydration-related kidney problems and severe gastrointestinal reactions. Low blood glucose may occur, particularly when these medicines are used with insulin or certain diabetes medications.
Persistent severe abdominal pain, repeated vomiting, dehydration or symptoms of a serious allergic reaction require prompt medical attention.
Patients should not increase, stop or change their prescribed dose without discussing it with their treating doctor.
Here is an outline of the step-by-step patient journey under the medical care of Dr. Komal Kulkarni:
Review of weight history, previous weight loss attempts, medical conditions, medications and treatment goals.
Assessment of BMI, waist circumference, blood pressure and relevant investigations, which may include HbA1c, lipid profile and kidney function tests.
Discussion of whether prescription injections are appropriate, available alternatives, expected benefits, limitations and potential risks.
If prescribed, guidance on injection technique, storage, dosing schedule and monitoring of treatment tolerance.
Regular review of weight, side effects, nutritional intake, physical activity and metabolic health, with treatment adjustments when needed.
Excess body weight and type 2 diabetes are often closely related. Increased body fat, particularly around the abdomen, can contribute to insulin resistance and make blood glucose management more challenging.
Certain GLP-1-based and dual GIP/GLP-1 medicines can support both weight reduction and glycaemic control. However, the choice of medicine depends on whether the primary treatment goal is diabetes management, weight management or both.
Patients already taking diabetes medicines may need closer glucose monitoring and medication adjustments to reduce the risk of hypoglycaemia.
A physician-led approach helps assess these factors together rather than focusing only on the number shown on the weighing scale.
Dr. Komal Kulkarni is a Consultant Physician and Diabetologist with qualifications including MBBS and DNB Medicine.
Her clinical background in general medicine and diabetes care is relevant when evaluating patients whose weight concerns coexist with conditions such as type 2 diabetes, hypertension or metabolic abnormalities.
During a weight management consultation, patients can discuss their medical history, previous weight loss attempts, available prescription options, treatment precautions and follow-up requirements.
The aim is to identify a medically appropriate approach based on the patient's overall health, rather than relying on a single treatment for every individual.
Weight loss medicines work best as part of a broader health management plan.
A sustainable approach may include balanced meals with adequate protein, fibre-rich foods, portion control, regular physical activity, strength training where appropriate, sufficient sleep and behavioural strategies for long-term weight maintenance.
Patients should also be monitored for inadequate nutrition, loss of muscle mass and difficulties maintaining weight after treatment changes.
The long-term goal is not simply weight reduction, but improvement in health and the development of sustainable habits.
If you are struggling with excess weight or have weight-related health concerns, a medical consultation can help identify appropriate treatment options.
Consult Dr. Komal Kulkarni, Consultant Physician and Diabetologist, to discuss your eligibility for weight loss injections, associated health conditions and long-term weight management.